On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.

On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.